Our top pick for
CytomX Therapeutics, Inc is a biotechnology business based in the US. CytomX Therapeutics shares (CTMX) are listed on the NASDAQ and all prices are listed in US Dollars. CytomX Therapeutics employs 158 staff and has a trailing 12-month revenue of around USD$92.3 million.
|Latest market close||USD$7.19|
|52-week range||USD$3.595 - USD$15.44|
|50-day moving average||USD$7.4476|
|200-day moving average||USD$7.4006|
|Wall St. target price||USD$12.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.2|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||-5.89%|
|1 month (2020-12-18)||-8.06%|
|3 months (2020-10-19)||7.47%|
|6 months (2020-07-17)||-16.64%|
|1 year (2020-01-17)||-3.62%|
|2 years (2019-01-18)||-57.10%|
|3 years (2018-01-19)||25.55|
|5 years (2016-01-19)||12.61|
|Revenue TTM||USD$92.3 million|
|Gross profit TTM||USD$57.5 million|
|Return on assets TTM||-11.9%|
|Return on equity TTM||-82.41%|
|Market capitalisation||USD$343 million|
TTM: trailing 12 months
There are currently 3.7 million CytomX Therapeutics shares held short by investors – that's known as CytomX Therapeutics's "short interest". This figure is 7.2% down from 4.0 million last month.
There are a few different ways that this level of interest in shorting CytomX Therapeutics shares can be evaluated.
CytomX Therapeutics's "short interest ratio" (SIR) is the quantity of CytomX Therapeutics shares currently shorted divided by the average quantity of CytomX Therapeutics shares traded daily (recently around 538923.82352941). CytomX Therapeutics's SIR currently stands at 6.8. In other words for every 100,000 CytomX Therapeutics shares traded daily on the market, roughly 6800 shares are currently held short.
However CytomX Therapeutics's short interest can also be evaluated against the total number of CytomX Therapeutics shares, or, against the total number of tradable CytomX Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CytomX Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 CytomX Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0667% of the tradable shares (for every 100,000 tradable CytomX Therapeutics shares, roughly 67 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CytomX Therapeutics.
Find out more about how you can short CytomX Therapeutics stock.
We're not expecting CytomX Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, CytomX Therapeutics's shares have ranged in value from as little as $3.595 up to $15.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CytomX Therapeutics's is 0.7486. This would suggest that CytomX Therapeutics's shares are less volatile than average (for this exchange).
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Everything we know about the Gold Royalty Corp IPO, plus information on how to buy in.
Everything we know about the Bustle Digital Group IPO, plus information on how to buy in.
Everything we know about the Lucid Motors IPO, plus information on how to buy in.
Steps to owning and managing HFFG, with 24-hour and historical pricing before you buy.
Steps to owning and managing HASI, with 24-hour and historical pricing before you buy.
Steps to owning and managing GRIF, with 24-hour and historical pricing before you buy.
Steps to owning and managing FSBW, with 24-hour and historical pricing before you buy.
Steps to owning and managing FNWB, with 24-hour and historical pricing before you buy.
Steps to owning and managing FXNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing FMNB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.